Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

Topline data were announced from a phase 3 trial evaluating varegacestat in patients with progressing desmoid tumors.

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

The Personal Financial Specialist (PFS) certification helps Certified Public Accountants (CPAs) demonstrate an expertise in all aspects of wealth management. A PFS is someone with a CPA who also ...

Varegacestat, an investigational gamma secretase inhibitor (GSI), delivered clinically meaningful improvements in efficacy outcomes vs placebo in patients with progressing desmoid tumors, according to ...

The combination of trabectedin (Yondelis; Pharma Mar, Johnson & Johnson) and olaparib (Lynparza; AstraZeneca, Merck) may be a meaningful treatment for certain patients with advanced soft tissue ...

Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer, the addition of ...

The Personal Finance Society (PFS) has announced that over 400 individuals have so far expressed interest in the PFS Pathway ...

BERLIN — Combining the off-the-shelf anticancer vaccine IO102-IO103 with pembrolizumab does not offer any progression-free survival (PFS) benefit in patients with untreated advanced melanoma vs ...

This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. This acquisition follows Apex Group’s longstanding partnership with PFS ...

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy reported ...